The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Official Title: A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma
Study ID: NCT00392444
Brief Summary: This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
Detailed Description: PRIMARY OBJECTIVES: I. Assess the efficacy of sunitinib malate, in terms of response rate (complete and partial), in patients with malignant pleural mesothelioma. II. Assess the toxicity, safety, and tolerability of this drug in these patients. III. Assess the duration of response or stable disease, stable disease rate, progression-free survival, and median and overall survival rates. OUTLINE: This is a multicenter, nonrandomized, open-label study. Patients are stratified according to prior cytotoxic chemotherapy (yes vs no). Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
Name: Scott Laurie
Affiliation: Canadian Cancer Trials Group
Role: PRINCIPAL_INVESTIGATOR